Korro Bio, Inc.

KRRO· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$10.35-12.29%

2026-09-18

Financials

Valuation Metrics

Korro Bio, Inc.'s Market Cap is $152M. At end of 2025 it was $75M. Ranked #3043 of 3,121 in US market (top 98%), #1399 of 1,463 on NASDAQ (top 96%), #257 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 97%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	$152M	US#3,043/3,121 Sec#257/266
Revenue	$2M	US#2,867/3,121 Sec#186/266
Net Income	$-107M	US—/3,121 Sec—/266
Total Assets	$163M	US#3,024/3,121 Sec#254/266
Net Assets	$103M	US#2,807/3,121 Sec#215/266
Employees	57	US#2,708/3,121 Sec#209/266
Value
P/B	1.48x	US#1,033/3,121 Sec#36/266
P/S	63.98x	US#2,937/3,121 Sec#172/266
FCF Yield	-44.79%	US—/3,121 Sec—/266
Profitability
ROE	-103.31%	US#2,796/3,121 Sec#204/266
ROA	-65.25%	US#3,026/3,121 Sec#234/266
Op. Margin	-3176.57%	US#2,850/3,121 Sec#174/266
Revenue Growth	-62.08%	US#2,752/3,121 Sec#168/266
Financial Health
Debt Ratio	58.34%	US#659/3,121 Sec#144/266
Total Debt	$42M	US#2,638/3,121 Sec#160/266
FCF	$-68M	US#2,573/3,121 Sec#123/266
Cash	$25M	US#2,815/3,121 Sec#252/266
Current Ratio	9.55x	US#271/3,121 Sec#84/266
Performance
1Y Return	-68.84%	US#3,020/3,121 Sec#250/266
1M Return	-25.81%	US#2,509/3,121 Sec#193/266
From 52W High	-81.48%	US#3,072/3,121 Sec#257/266
1Y MDD	-89.72%	US#3,110/3,121 Sec#262/266
Trading
Volume	590,920 shares	US#2,230/3,121 Sec#228/266
Trading Value	$6M	US#2,671/3,121 Sec#222/266
Per Share
EPS	$-7.24	US—/3,121 Sec—/266
BPS	$7.01	US#2,089/3,121 Sec#99/266

Company Info

CEO Ram Aiyar

Employees 57

HQ Cambridge, US

Website https://www.korrobio.com

Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.